01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#POLB Poolbeg Pharma PLC – Interim Results for the six months to 30 June 2025 September 29, 2025 – Posted in: Poolbeg Pharma (POLB)

  29 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025. Highlights & Updates • Cash balance of £10.0 million as at 30 June 2025, including £4.865 million gross proceeds raised as part of an oversubscribed and upsized fundraise • Cash runway extended into 2027, supporting the delivery of multiple…

Continue reading

#POLB Poolbeg Pharma PLC – POLB 001 Phase 2a Trial Update September 25, 2025 – Posted in: Poolbeg Pharma (POLB)

25 September 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the Company has signed an agreement for a specialist blood cancer trials organisation, Accelerating Clinical Trials Limited (“ACT”), to conduct the upcoming POLB 001 Phase 2a trial and has also secured the supply of an approved bispecific antibody drug for the trial at no cost to the Company. The…

Continue reading

Safer Space – Creating Healthier Environments. CEO Roy Winters talks to Alan Green April 15, 2025 – Posted in: Blog, Safer Space

Safer Space – Creating Healthier Environments. CEO Roy Winters talks to Alan Green. UK company Safer Space creates healthier environments by reducing the presence of living germs and viruses known as pathogens, in all the environments you might visit through the application of its innovative independent cleaning and hygiene standard. As part of its growth strategy, Safer Space is scheduled to list on a public market in 2025. Roy discusses the challenges faced in tackling…

Continue reading

Open Orphan PLC #ORPH – NEJM Opinion Piece July 22, 2021 – Posted in: Open Orphan (ORPH)

The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government’s Human Challenge Programme has been published in the latest edition of the New England Journal of Medicine (NEJM). The piece, titled ‘Establishing the Model during an Evolving Pandemic’, explores the extensive…

Continue reading